NEUMORA THERAPEUTICS, INC. Accounts Payable
NEUMORA THERAPEUTICS, INC. (NMRA) had Accounts Payable of $4.15 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-14
- 2026-06-30: Accounts Payable, Current $4.15M.
- 2026-03-31: Accounts Payable, Current $5.06M.
- 2025-12-31: Accounts Payable, Current $3.38M.
- 2025-09-30: Accounts Payable, Current $549.00K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $4.15M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $5.06M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.38M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $549.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $644.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.05M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $3.31M 10-K · filed 2026-03-30 |
| 2024-09-30 | $6.11M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.08M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.49M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $337.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $2.23M 10-Q · filed 2023-11-01 |
| 2022-12-31 | $7.15M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |